DE2606516C2 - - Google Patents
Info
- Publication number
- DE2606516C2 DE2606516C2 DE2606516A DE2606516A DE2606516C2 DE 2606516 C2 DE2606516 C2 DE 2606516C2 DE 2606516 A DE2606516 A DE 2606516A DE 2606516 A DE2606516 A DE 2606516A DE 2606516 C2 DE2606516 C2 DE 2606516C2
- Authority
- DE
- Germany
- Prior art keywords
- hydrocortisone
- propylene glycol
- agent
- effective
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 50
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 45
- 229960000890 hydrocortisone Drugs 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 239000006071 cream Substances 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 150000003431 steroids Chemical class 0.000 description 9
- 239000000243 solution Substances 0.000 description 5
- 239000003883 ointment base Substances 0.000 description 4
- 230000001804 emulsifying effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960000785 fluocinonide Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- -1 "fluocinonide" Chemical class 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7030/75A GB1543907A (en) | 1975-02-19 | 1975-02-19 | Steroid compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2606516A1 DE2606516A1 (de) | 1976-09-02 |
| DE2606516C2 true DE2606516C2 (enrdf_load_stackoverflow) | 1987-09-17 |
Family
ID=9825303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19762606516 Granted DE2606516A1 (de) | 1975-02-19 | 1976-02-18 | Entzuendungshemmendes mittel zur lokalen anwendung |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS609486B2 (enrdf_load_stackoverflow) |
| AU (1) | AU502937B2 (enrdf_load_stackoverflow) |
| DE (1) | DE2606516A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2341317A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1543907A (enrdf_load_stackoverflow) |
| IE (1) | IE43270B1 (enrdf_load_stackoverflow) |
| ZA (1) | ZA76980B (enrdf_load_stackoverflow) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR830005852A (ko) * | 1980-07-18 | 1983-09-14 | 미첼 페터 잭슨 | 피부와 점막의 비루스 감염치료에 적합한 국소치료제의 제조방법 |
| GB2080106B (en) * | 1980-07-18 | 1984-03-07 | Weelcome Foundation Ltd | Acyclovin preparations |
| JPS59137408A (ja) * | 1983-01-27 | 1984-08-07 | Taisho Pharmaceut Co Ltd | 軟膏 |
| AT389447B (de) * | 1983-01-27 | 1989-12-11 | Taisho Pharmaceutical Co Ltd | Verfahren zur herstellung einer topischen steroidsalbe |
| JPS59139315A (ja) * | 1983-01-31 | 1984-08-10 | Taisho Pharmaceut Co Ltd | クリ−ム剤 |
| WO1996020712A1 (en) * | 1994-12-30 | 1996-07-11 | American Home Products Corporation | Clear non-alcoholic hydrocortisone solutions |
| GB2302808A (en) * | 1995-07-04 | 1997-02-05 | Surtech Int Ltd | Propylene glycol with low potency corticosteroids for topical treatment of the scalp |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA725898B (en) * | 1972-05-30 | 1973-05-30 | Sackler R | Iodophor steroid pharmaceutical compositions |
| US3892857A (en) * | 1972-11-24 | 1975-07-01 | Squibb & Sons Inc | Steroid formulation |
-
1975
- 1975-02-19 GB GB7030/75A patent/GB1543907A/en not_active Expired
-
1976
- 1976-02-11 IE IE269/76A patent/IE43270B1/en unknown
- 1976-02-18 FR FR7604443A patent/FR2341317A1/fr active Granted
- 1976-02-18 DE DE19762606516 patent/DE2606516A1/de active Granted
- 1976-02-18 ZA ZA980A patent/ZA76980B/xx unknown
- 1976-02-18 JP JP51016083A patent/JPS609486B2/ja not_active Expired
- 1976-02-19 AU AU11232/76A patent/AU502937B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IE43270B1 (en) | 1981-01-28 |
| GB1543907A (en) | 1979-04-11 |
| ZA76980B (en) | 1977-01-26 |
| AU1123276A (en) | 1977-08-25 |
| IE43270L (en) | 1976-08-19 |
| AU502937B2 (en) | 1979-08-16 |
| FR2341317A1 (fr) | 1977-09-16 |
| FR2341317B1 (enrdf_load_stackoverflow) | 1979-06-08 |
| JPS609486B2 (ja) | 1985-03-11 |
| JPS51106713A (enrdf_load_stackoverflow) | 1976-09-21 |
| DE2606516A1 (de) | 1976-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2448871C3 (de) | Stabilisierung von trans-Retinsäurecreme | |
| DE2046119C2 (de) | Mittel zur Behandlung von Akne | |
| DE2747631C3 (de) | Salbe | |
| DE2818553A1 (de) | Zusammensetzung zur behandlung von proliferativen hautkrankheiten | |
| CH668188A5 (en) | Corticosteroid ointment compsns. - comprise e.g. dexamethasone in poly:alkylene glycol base, and are used esp. for treating rhinitis | |
| EP0367103B1 (de) | Topische Salbe | |
| DE2355710C2 (de) | Steroidhaltige Creme zur lokalen Behandlung von Hauterkrankungen | |
| DE60004786T2 (de) | Verfahren und zusammensetzung zur behandlung von akne | |
| DE2514873C2 (de) | Salbengrundlage | |
| DE2818827C2 (de) | Mittel zur Behandlung von Psoriasis | |
| DE3411225C2 (enrdf_load_stackoverflow) | ||
| DE2606516C2 (enrdf_load_stackoverflow) | ||
| DE3139519A1 (de) | "topisch verabreichbare pharmazeutische zusammensetzungen, enthaltend anti-inflammatorische steroide" | |
| DE1617320C3 (de) | Hautbehandlungsmittel | |
| DE1804801C3 (de) | Mittel zur Aknebehandlung | |
| EP0432638B1 (de) | Kombinationspräparate enthaltend Chloramphenicol, Gentamicin und Nystatin als aktive Wirkstoffe zur topischen Behandlung entzündlicher Hauterkrankungen | |
| DE2609575C2 (de) | Kosmetisches Präparat | |
| DE3402877C2 (enrdf_load_stackoverflow) | ||
| DE1949740A1 (de) | Hautschutzmischung und Verfahren zu ihrer Herstellung | |
| DD153759A5 (de) | Haarpflegemittel zur aeusseren anwendung | |
| DE3020616C2 (enrdf_load_stackoverflow) | ||
| DE2851369A1 (de) | Lokalanaesthetische emulsionscreme, verfahren zu deren herstellung und deren verwendung | |
| DE2851544C2 (de) | Fluocortolon-haltige Creme | |
| DE4319096C1 (de) | Hormonales Mittel zur Vorbeugung und Behandlung arterieller Erkrankungen beim Mann | |
| DE2604201A1 (de) | Kosmetisches haarpflegemittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8127 | New person/name/address of the applicant |
Owner name: DIOMED DEVELOPMENTS LTD., GOSMORE, HITCHIN, HERTFO |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |